Celltrion has revealed fresh one-year Phase III trial data for its Yuflyma (adalimumab) biosimilar rival to Humira as it begins the process of rolling out the product – the world’s first approved higher-strength adalimumab biosimilar – in various markets in Europe.
As it announced its recent first-quarter results, Celltrion indicated that it planned to have launched Yuflyma in more than 70%...